Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Up 257.5% in January

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 27,898 shares, a growth of 257.5% from the January 15th total of 7,804 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily volume of 638,622 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 638,622 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.3% of the shares of the company are sold short.

Analyst Ratings Changes

A number of brokerages recently commented on LSTA. Zacks Research downgraded Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Brookline Capital Acquisition downgraded shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Lisata Therapeutics presently has an average rating of “Hold” and an average target price of $23.50.

Lisata Therapeutics Stock Performance

Shares of NASDAQ:LSTA traded up $0.02 during trading on Friday, reaching $4.57. The company had a trading volume of 99,208 shares, compared to its average volume of 280,207. The firm’s fifty day moving average is $2.86 and its 200 day moving average is $2.54. The firm has a market capitalization of $40.31 million, a PE ratio of -2.15 and a beta of 1.25. Lisata Therapeutics has a twelve month low of $1.81 and a twelve month high of $4.89.

Hedge Funds Weigh In On Lisata Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LSTA. Ground Swell Capital LLC acquired a new position in shares of Lisata Therapeutics in the third quarter worth about $62,000. Renaissance Technologies LLC boosted its holdings in shares of Lisata Therapeutics by 6.1% during the fourth quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after purchasing an additional 7,093 shares during the period. CIBC Bancorp USA Inc. purchased a new position in Lisata Therapeutics during the third quarter valued at approximately $37,000. Finally, Cerity Partners LLC acquired a new position in Lisata Therapeutics in the 2nd quarter valued at approximately $32,000. 8.94% of the stock is owned by institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.